Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Depreciation & Amortization (CF): 2010-2025

Historic Depreciation & Amortization (CF) for Altimmune (ALT) over the last 16 years, with Sep 2025 value amounting to $27,000.

  • Altimmune's Depreciation & Amortization (CF) fell 27.03% to $27,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $119,000, marking a year-over-year decrease of 65.20%. This contributed to the annual value of $238,000 for FY2024, which is 52.40% down from last year.
  • Latest data reveals that Altimmune reported Depreciation & Amortization (CF) of $27,000 as of Q3 2025, which was down 10.00% from $30,000 recorded in Q2 2025.
  • In the past 5 years, Altimmune's Depreciation & Amortization (CF) registered a high of $285,000 during Q3 2021, and its lowest value of -$552,000 during Q3 2023.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $30,000 (2025), whereas its average is -$86,545.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first spiked by 291.02% in 2021, then plummeted by 1,052.83% in 2023.
  • Altimmune's Depreciation & Amortization (CF) (Quarterly) stood at $117,000 in 2021, then crashed by 301.71% to -$236,000 in 2022, then spiked by 158.05% to $137,000 in 2023, then slumped by 75.91% to $33,000 in 2024, then dropped by 27.03% to $27,000 in 2025.
  • Its Depreciation & Amortization (CF) was $27,000 in Q3 2025, compared to $30,000 in Q2 2025 and $29,000 in Q1 2025.